Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report released on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of EVOK opened at $4.42 on Monday. Evoke Pharma has a one year low of $3.54 and a one year high of $13.80. The company has a market cap of $6.57 million, a PE ratio of -0.40 and a beta of 0.16. The stock has a 50-day moving average of $4.87 and a 200-day moving average of $5.21.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.